% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Dimopoulos:142330,
      author       = {M. A. Dimopoulos and D. Dytfeld and S. Grosicki and P.
                      Moreau and N. Takezako and M. Hori and X. Leleu and R.
                      LeBlanc and K. Suzuki and M.-S. Raab$^*$ and P. G.
                      Richardson and M. Popa McKiver and Y.-M. Jou and S. G.
                      Shelat and M. Robbins and B. Rafferty and J. San-Miguel},
      title        = {{E}lotuzumab plus {P}omalidomide and {D}examethasone for
                      {M}ultiple {M}yeloma.},
      journal      = {The New England journal of medicine},
      volume       = {379},
      number       = {19},
      issn         = {1533-4406},
      address      = {Waltham, Mass.},
      publisher    = {MMS},
      reportid     = {DKFZ-2019-00106},
      pages        = {1811 - 1822},
      year         = {2018},
      abstract     = {The immunostimulatory monoclonal antibody elotuzumab plus
                      lenalidomide and dexamethasone has been shown to be
                      effective in patients with relapsed or refractory multiple
                      myeloma. The immunomodulatory agent pomalidomide plus
                      dexamethasone has been shown to be effective in patients
                      with multiple myeloma that is refractory to lenalidomide and
                      a proteasome inhibitor.Patients with multiple myeloma that
                      was refractory or relapsed and refractory to lenalidomide
                      and a proteasome inhibitor were randomly assigned to receive
                      elotuzumab plus pomalidomide and dexamethasone (elotuzumab
                      group) or pomalidomide and dexamethasone alone (control
                      group). The primary end point was investigator-assessed
                      progression-free survival.A total of 117 patients were
                      randomly assigned to the elotuzumab group (60 patients) or
                      the control group (57 patients). After a minimum follow-up
                      period of 9.1 months, the median progression-free survival
                      was 10.3 months in the elotuzumab group and 4.7 months in
                      the control group. The hazard ratio for disease progression
                      or death in the elotuzumab group as compared with the
                      control group was 0.54 $(95\%$ confidence interval [CI],
                      0.34 to 0.86; P=0.008). The overall response rate was $53\%$
                      in the elotuzumab group as compared with $26\%$ in the
                      control group (odds ratio, 3.25; $95\%$ CI, 1.49 to 7.11).
                      The most common grade 3 or 4 adverse events were neutropenia
                      $(13\%$ in the elotuzumab group vs. $27\%$ in the control
                      group), anemia $(10\%$ vs. $20\%),$ and hyperglycemia $(8\%$
                      vs. $7\%).$ A total of $65\%$ of the patients in each group
                      had infections. Infusion reactions occurred in 3 patients
                      $(5\%)$ in the elotuzumab group.Among patients with multiple
                      myeloma in whom treatment with lenalidomide and a proteasome
                      inhibitor had failed, the risk of progression or death was
                      significantly lower among those who received elotuzumab plus
                      pomalidomide and dexamethasone than among those who received
                      pomalidomide plus dexamethasone alone. (Funded by
                      Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-3
                      ClinicalTrials.gov number, NCT02654132 .).},
      keywords     = {Antibodies, Monoclonal, Humanized (NLM Chemicals) /
                      Immunologic Factors (NLM Chemicals) / elotuzumab (NLM
                      Chemicals) / Thalidomide (NLM Chemicals) / Dexamethasone
                      (NLM Chemicals) / pomalidomide (NLM Chemicals)},
      cin          = {G170},
      ddc          = {610},
      cid          = {I:(DE-He78)G170-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30403938},
      doi          = {10.1056/NEJMoa1805762},
      url          = {https://inrepo02.dkfz.de/record/142330},
}